within Pharmacolibrary.Drugs.ATC.S;

model S01EX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 30 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ripasudil is a Rho-associated protein kinase (ROCK) inhibitor used as an ophthalmic solution for the treatment of glaucoma and ocular hypertension. It acts to lower intraocular pressure by increasing outflow of aqueous humor through the trabecular meshwork. It is approved in Japan for ocular use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for ophthalmic administration in adult subjects; no published compartmental PK model available.</p><h4>References</h4><ol><li><p>Tanihara, H, et al., &amp; Suganami, H (2023). Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine. <i>Advances in therapy</i> 40(8) 3559–3573. DOI:<a href=&quot;https://doi.org/10.1007/s12325-023-02534-w&quot;>10.1007/s12325-023-02534-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37330927/&quot;>https://pubmed.ncbi.nlm.nih.gov/37330927</a></p></li><li><p>Isobe, T, et al., &amp; Kawai, H (2016). Ocular Penetration and Pharmacokinetics of Ripasudil Following Topical Administration to Rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 32(7) 405–414. DOI:<a href=&quot;https://doi.org/10.1089/jop.2016.0028&quot;>10.1089/jop.2016.0028</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27463221/&quot;>https://pubmed.ncbi.nlm.nih.gov/27463221</a></p></li><li><p>Testa, V, et al., &amp; Iester, M (2020). An update on ripasudil for the treatment of glaucoma and ocular hypertension. <i>Drugs of today (Barcelona, Spain : 1998)</i> 56(9) 599–608. DOI:<a href=&quot;https://doi.org/10.1358/dot.2020.56.9.3178110&quot;>10.1358/dot.2020.56.9.3178110</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33025953/&quot;>https://pubmed.ncbi.nlm.nih.gov/33025953</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01EX07;
